Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials

Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials

BackgroundCurrently, disease-modifying therapies (DMTs) for progressive multiple sclerosis (PMS) are widely used in clinical practice. At the same time, there are a variety of drug options for DMTs, but the effect of the drugs that can better relieve symptoms and improve the prognosis are still inco...

Full description

Bibliographic Details
Main Authors: Xin Wu, Shixin Wang, Tao Xue, Xin Tan, Jiaxuan Li, Zhouqing Chen, Zhong Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
disease-modifying therapy
randomized controlled
ocrelizumab
natalizumab
rituximab
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1295770/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2024.1295770/full

Similar Items